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To the editor: In their recent rapid communication in 
‘Rapid response infrastructure for pandemic prepared-
ness in a tertiary care hospital: lessons learned from 
the COVID-19 outbreak in Cologne, Germany, February 
to March 2020’ [1], Augustin et al. describe how a rapid 
response infrastructure was established to manage 
large numbers of suspected and confirmed coronavi-
rus disease (COVID-19) cases in a German university 
hospital.
Their description is an example of the exceptional 
effort and adaptability of healthcare providers, that 
helped limit nosocomial transmission and hospital out-
breaks in Germany in the first months of the COVID-19 
pandemic. It also demonstrates that timely case-based 
information provided by clinicians and laboratories 
is invaluable for the development and adaptation of 
data-driven guidelines. Such information is therefore 
collected via the German national surveillance system. 
The Robert Koch Institute (RKI), Germany’s national 
public health institute, used the information on the 
likely place of infection as a criterion for the definition 
of international risk areas (alongside local incidence, 
epidemic trend, measures taken, origin of interna-
tionally exported cases and transport connectivity to 
Germany).
We would thus like to point out, that Augustin et al. did 
not act against, but in compliance with national guide-
lines when they tested patients without travel history 
to a declared risk area for severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2). On the contrary, 
RKI relies on clinicians to remain vigilant, to include 
COVID-19 in their differential diagnosis and to routinely 
question patients about their travel history.
On 17 January 2020, RKI first published a guidance for 
doctors on measures and testing criteria for suspected 
COVID-19 cases [2]. Therapeutic freedom, including 
diagnostic decision-making of medical practitioners 
is guaranteed by German law. Similar to all technical 
guidelines by RKI, the guidance on testing criteria and 
measures is not binding. It aims to provide orienta-
tion for clinicians as to when testing for SARS-CoV-2 is 
especially recommended, and when suspected COVID-
19-cases require specific infection prevention and 
control measures as well as immediate notification to 
local public health authorities. This document is being 
constantly adapted to the developing epidemiological 
situation. The version history is available online at: 
https://edoc.rki.de/handle/176904/6459 and https://
edoc.rki.de/handle/176904/6484.11.
Until 11 March 2020, COVID-19 was not considered a 
pandemic by the World Health Organization (WHO). It 
is important to note that towards the end of February 
and beginning of March, the influenza season was still 
active and full SARS CoV-2 testing capacity was not 
yet established in Germany. It would thus not have 
been feasible to recommend SARS-CoV-2 testing for 
everybody irrespective of clinical symptoms and risk 
exposure.
Risk exposure was defined as (i) having had contact to a 
confirmed case or (ii) travel history to a risk area. From 
12 February, SARS-CoV-2-testing was additionally rec-
ommended for individuals with clinical signs (without 
alternative explanation), who did not report risk expo-
sure as defined above, but rather had a travel history 
to any region in the world where COVID-19-cases had 
been confirmed, including specific regions in Germany. 
To inform both health professionals and the public, RKI 
published updated case numbers worldwide including 
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considerations on which geographical regions were 
actually considered ‘risk areas’.
At the end of February 2020, RKI re-emphasised the 
importance of including COVID-19 in the differential 
diagnosis in individuals, who had a travel history to 
a region where COVID-19-cases had been confirmed, 
even if it was not defined as ‘risk area’. However, 
in contrast to individuals with travel history to ‘risk 
areas’, these patients were not regarded as suspected 
cases. Hence, it was not recommended to strictly iso-
late them and to immediately notify them to public 
health authorities.
The valuable description of Augustin et al. demon-
strates that RKI’s national guidelines were known and 
applied in German hospitals to guide clinicians’ deci-
sion-making and management of potential cases. The 
paper also demonstrates the value of exceptional com-
mitment by clinicians. Moreover, it suggests that dur-
ing the evolving pandemic there may have been delays 
in frequent updates reaching frontline clinicians. 
Augustin et al.’s case study highlights the importance 
of well-established communication channels between 
public health authorities and healthcare providers, and 
the need for their further improvement to even better 
prepare for the next wave of COVID-19.
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